National Pension Service Purchases 37,363 Shares of DexCom, Inc. (NASDAQ:DXCM)

National Pension Service raised its holdings in shares of DexCom, Inc. (NASDAQ:DXCM) by 4.1% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 949,743 shares of the medical device company’s stock after purchasing an additional 37,363 shares during the period. National Pension Service owned 0.24% of DexCom worth $63,671,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently modified their holdings of the company. Taylor Frigon Capital Management LLC boosted its stake in DexCom by 51.6% in the third quarter. Taylor Frigon Capital Management LLC now owns 32,554 shares of the medical device company’s stock valued at $2,182,000 after acquiring an additional 11,075 shares during the last quarter. Waters Parkerson & CO. LLC lifted its stake in shares of DexCom by 4.2% in the 2nd quarter. Waters Parkerson & CO. LLC now owns 272,641 shares of the medical device company’s stock valued at $30,912,000 after purchasing an additional 10,892 shares during the period. Legal & General Group Plc grew its stake in shares of DexCom by 1.7% during the second quarter. Legal & General Group Plc now owns 2,993,049 shares of the medical device company’s stock worth $339,352,000 after purchasing an additional 49,076 shares during the period. Factory Mutual Insurance Co. increased its holdings in DexCom by 136.1% in the third quarter. Factory Mutual Insurance Co. now owns 404,230 shares of the medical device company’s stock valued at $27,100,000 after purchasing an additional 233,000 shares during the last quarter. Finally, Healthcare of Ontario Pension Plan Trust Fund lifted its stake in DexCom by 533.1% in the second quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 36,510 shares of the medical device company’s stock valued at $4,140,000 after buying an additional 30,743 shares during the period. Institutional investors own 97.75% of the company’s stock.

Insiders Place Their Bets

In related news, COO Jacob Steven Leach sold 746 shares of the firm’s stock in a transaction on Monday, September 9th. The shares were sold at an average price of $69.15, for a total value of $51,585.90. Following the completion of the transaction, the chief operating officer now directly owns 264,915 shares of the company’s stock, valued at approximately $18,318,872.25. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, COO Jacob Steven Leach sold 746 shares of the firm’s stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $69.15, for a total value of $51,585.90. Following the completion of the sale, the chief operating officer now directly owns 264,915 shares in the company, valued at approximately $18,318,872.25. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP Sadie Stern sold 426 shares of the company’s stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $69.15, for a total value of $29,457.90. Following the completion of the sale, the executive vice president now owns 75,451 shares in the company, valued at $5,217,436.65. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders own 0.30% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on DXCM shares. StockNews.com lowered DexCom from a “buy” rating to a “hold” rating in a research report on Saturday. Oppenheimer lowered their target price on shares of DexCom from $115.00 to $105.00 and set an “outperform” rating for the company in a research note on Friday, October 25th. Stifel Nicolaus increased their target price on shares of DexCom from $90.00 to $100.00 and gave the stock a “buy” rating in a report on Friday, August 23rd. Raymond James decreased their price target on shares of DexCom from $115.00 to $99.00 and set a “strong-buy” rating for the company in a report on Friday, October 25th. Finally, UBS Group dropped their price objective on DexCom from $163.00 to $95.00 and set a “buy” rating on the stock in a research note on Friday, July 26th. Seven equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, DexCom has a consensus rating of “Moderate Buy” and a consensus target price of $104.59.

DexCom Stock Performance

DXCM opened at $69.00 on Wednesday. The business’s 50-day simple moving average is $69.70 and its 200 day simple moving average is $94.48. DexCom, Inc. has a 52-week low of $62.34 and a 52-week high of $142.00. The company has a debt-to-equity ratio of 1.23, a quick ratio of 2.12 and a current ratio of 2.46. The firm has a market capitalization of $26.95 billion, a PE ratio of 41.32, a PEG ratio of 2.16 and a beta of 1.17.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.